TG Therapeutics Inc (NASDAQ:TGTX)

13.50
Delayed Data
As of Jan 24
 -0.05 / -0.37%
Today’s Change
3.87
Today|||52-Week Range
14.89
+21.62%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.3B

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
2 Gansevoort Street
New York New York 10014
P:(212) 554-4484
Investor Relations:
1212

Employees

Shareholders

Individual stakeholders9.25%
Other institutional37.93%
Mutual fund holders16.47%

Top Executives

There are no executives to display.